Latarjet Procedure: Comparative Outcomes Study of Arthroscopic Versus Mini-open Approach With Minimum 2-year Follow-up (Latarjet)
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
-
Boulogne-Billancourt, France, 92000
- Hospital Ambroise Paré Paris
-
Paris, France
- Clinique des Maussins
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- chronic anterior instability requiring bone grafting (Instability Severity Index Score>3)
Exclusion Criteria:
- Patient refusal
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Arthroscopic Latarjet procedure
arthroscopic approach (set Depuy-Mitek, Raynham, MA)
|
arthroscopic approach (set Depuy-Mitek, Raynham, MA)
|
|
Mini-open Latarjet procedure
mini-open approach (set Arthrex, Naples, FL)
|
mini-open approach (set Arthrex, Naples, FL)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Average postoperative shoulder's pain on visual analogic scale from 0 (no pain) to 10 (maximum pain)
Time Frame: Average during the first week
|
Average during the first week
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Mean daily pain on visual analogic scale from 0 (no pain) to 10 (maximum pain)
Time Frame: Daily from day1 to day7
|
Daily from day1 to day7
|
|
|
analgesic consumption (Number of pills)
Time Frame: Daily from day1 to day7
|
Daily from day1 to day7
|
|
|
presence of postoperative discomfort symptoms (yes/no)
Time Frame: Daily from day1 to day7
|
The presence (yes/no) of incision site pain, nausea, vomiting, vertigo, anxiety
|
Daily from day1 to day7
|
|
coracoid bone block position to the anterior aspect of the glenoid on the anterior-posterior and the lateral X-ray and on CT-scan
Time Frame: Between 3 to 6 months follow-up
|
Between 3 to 6 months follow-up
|
|
|
Recurrence rate of shoulder instability (number of recurrence/total number of patients)
Time Frame: 2-year minimal follow-up
|
2-year minimal follow-up
|
|
|
Functional evaluation of patients
Time Frame: 2-year minimal follow-up
|
Western Ontario Score Index (WOSI)
|
2-year minimal follow-up
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Shahnaz Klouche, MD, Hospital Ambroise Paré Paris
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- APR012012
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.